Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-masked, multicenter, parallel-assignment, pilot study
to evaluate the safety, tolerability, initial clinical effectiveness, pharmacokinetics (PK),
and immunogenicity of SCB-420 as compared with Eylea (aflibercept), in subjects with
Neovascular Age-related Macular Degeneration.
A total of 20 subjects with Neovascular Age-related Macular Degeneration will be enrolled
across up to 11 sites in 3 countries (Australia, New Zealand, and China). The study will be
conducted in 2 parts - Sentinel Safety Cohort and Open Enrolment. Subjects will be
administered with 2 mg of SCB-420 or Eylea via intravitreal (IVT) injection every 4 weeks for
a total 3 doses.